Skip to content

Mechanistic Exploration of Aspirin's Preventive Role in Preeclampsia Based on HMGB1

Mechanistic Exploration of Aspirin's Preventive Role in Preeclampsia Based on HMGB1

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081498
Enrollment
Unknown
Registered
2024-03-04
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

Observation group :None
Control group:None

Sponsors

Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1)12-20 weeks of gestation, single fetus; (2)Preeclampsia high-risk groups: 1) Those who meet any of the following conditions: previous history of preeclampsia, chronic hypertension, type I or type II diabetes, kidney disease, autoimmune disease (such as antiphospholipid antibody syndrome, systemic lupus erythematosus); 2) Those who meet two or more of the following criteria: obesity (BMI=28kg/m2), age =35 years, primipara, family history of preeclampsia (mother or sister); Personal history (low birth weight or small for gestational age, previous history of adverse pregnancies, interval > 10 years between previous pregnancies). (3)Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnancy by assisted reproductive technology; (2) A history of smoking and drinking; (3) There is contraindication of aspirin.

Design outcomes

Primary

MeasureTime frame
Serum HMGB1 concentration;Platelet aggregation rate;

Secondary

MeasureTime frame
Plasma prothrombin time;Thrombin time;Partial activation of thromboplastin time;Plasma fibrinogen;D-dimer;

Countries

China

Contacts

Public ContactChen Huajiao

Fujian Maternity and Child Health Hospital

83962600@qq.com+86 135 5944 8669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026